EXHIBIT 99.2

For more information contact:

John Stanton
813-264-2241



FOR IMMEDIATE RELEASE


           Nanobac Pharmaceuticals, Inc. announces New Leadership Team

TAMPA, Fla. (January 29, 2003)-- Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP)
("Nanobac" or "The Company").

     John Stanton, Chairman of the Board, announced effective 01/29/04 the
following organization changes: Mr. Stanton said this was in keeping with an
earlier announcement to bring on board a strong team of NanoTechnology
Scientists and Researchers, as well as experienced professionals in the BioLife
Sciences business.

     Alexander H. Edwards, III will become President/Chief Executive Officer and
Board member of Nanobac Pharmaceuticals, Inc. Prior to joining Nanobac, Edwards
was a managing partner of 360 Partners as well as president and CEO of 360
Energy. Before that, he was in private consulting practice utilizing his
experiences with leadership in healthcare growth companies.

From January 1997 to May 2002, Edwards was an executive with SRI/Surgical
Express. He served in roles that ranged from vice-president/general manager to
spending his last year with the company as president. Previous to this, he
worked in sales and marketing with Dianon Systems, Inc. His positions included
sales and sales management roles as well as field and corporate marketing.
Edwards also served as an officer in the United States Navy with duty
assignments ranging from shipboard divisional leadership to executive assistant
for the Naval Surface Group Commander in Norfolk, Virginia.

     Edwards is a 1987 graduate of the United States Naval Academy.

     Brady Millican will replace Mr. Edwards as Vice President/Chief Operating
Officer for the company. Mr. Millican has over 12 years of leadership experience
and a comprehensive background in diagnostics infrastructure including clinical
trial and research development support. Prior to joining Nanobac, Brady was
Director of Business Development and Strategic projects at AmeriPath, a leading
national provider of cancer diagnostics, genomics, and related information
services.

     Previous to this he worked at Pathology Service Associates in various
leadership roles ranging from directing marketing activities to developing
revenue enhancement audits. Millican also worked at Dianon Systems, Inc. in
Sales and sales management roles, as well as field and corporate marketing.

Millican served as an officer in the United States Army as a helicopter pilot,
and is airborne and ranger qualified. Millican received his Bachelor of Arts
Degree in Psychology (emphasis in Industrial Psychology - motivation) from
Washington and Lee University in 1983.


     Michael Dean will continue as Controller. He has a B.A. in Accounting and
obtained his B.A. in Accounting Information systems from the University of West
Florida in 1983. In addition, he obtained his CPA in 1985.



     He started his career at Shell Oil Company, then became a Staff Accountant
at Harper VanScoik & Company, a regional CPA firm. Then to CGI (IMR Global Corp)
where he served as Controller, then V.P. of Finance and Chief Financial Officer.
Dean brings 19 years of knowledge in Finance, Taxes, SEC filing and
International experience.

     For additional information refer to Bios on our website,
www.nanobaclabs.com, under the heading, "The Company".

     Mr. Stanton also announced the complete restructuring of the Research and
Science Institution.

     With the completion of the acquisition of Nanobac OY in Kuopio, Finland, it
is now possible to combine all the company's intellectual knowledge in to one
group.

     The new group will be Nanobac Science and Research Institute, a division of
Nanobac Pharmaceuticals, Inc., with offices in Kuopio, Finland and Tampa,
Florida. This group is recognized as the world leaders in the Science and
Research of Nanobacteria sanguineum, it's effects and causes, and the diseases
that are implicated.

     Dr. Olavi Kajander, MD, PhD will be the Managing Director of Nanobac OY and
Chief Science & Research Officer for the company. Dr. Kajander is the founder of
Nanobac OY, a Finnish research and development company located in Kuopio,
Finland, where, along with Dr. Neva Ciftcioglu, he documented and patented their
discovery of Nanobacteria. Nanobac OY is now a Finnish research subsidiary of
Nanobac Pharmaceuticals, Inc. He was also the founder of Abcell Corporation, a
medical diagnostics company.

     In addition to being the Chief of Science and Research Officer at Nanobac,
Dr. Kajander is also a docent (full professor) and director of research of the
department of biochemistry at the University of Kuopio (Kuopio, Finland). His
position at the University of Kuopio has elevated over the time of his tenure
from Ph.D. candidate, to doctorate, assistant professor, associate professor and
now as docent. He has taught many courses at the university for more than 12
years.

     Dr. Kajander was a Scripps Clinic & Resident Foundation post-doctoral
research fellow in La Jolla, California. He has authored more than 70 scientific
research papers and review articles, two letters and more than 50 scientific
abstract publications as well as several invited editorials in scientific texts
and journals. He has also been involved in the production of a number of videos
and documentaries about his discovery of Nanobacteria. He has two families of
U.S. patents that are effective in many countries and another family of U.S.
patents that are pending issue.

     In 1999, together with fellow researcher Dr. Neva Ciftcioglu, Dr. Kajander
won the Minerva, Medix award for the most prominent Finnish biomedical paper of
1998. He has also won the Martti Hamalainen Young Researcher Award, the Swedish
Medical Association, Riksmassan, Honorary Bronze Medal and the Korczynski Award
and Honorarium for the advancement of biopharmaceutical sciences.

     Dr. Kajander is a member of the Biochemical Society, the New York Academy
of Sciences, FEMS, the Finnish Immunology Society, the Finnish Physiology
Society and Duodecim. He has also served on numerous scientific advisory boards.

     Dr. Neva Ciftcioglu, PhD will serve as Scientific Advisor to the company.
Born in Turkey, Neva Ciftcioglu, Ph.D. is a co-discoverer and a principal
researcher of Nanobacterium sanguineum with Dr. E. Olavi Kajander. Dr.
Ciftcioglu has been a scientific collaborator with NanobacLabs Research
Institute since 1999. Drs. Ciftcioglu and Kajander are regarded as the world's
experts in Nanobacterial research. While her early work centered on general
infectious diseases and bacterial pathogencity, her recent area of interest is
in cell culture techniques, immunoassays and monoclonal antibodies and
nanobacterial pathogenicity.



     She is a Docent (full professor) of biochemistry at the University of
Kuopio in Kuopio, Finland and a senior scientist and director of nanobacterial
research for the Universities Space Research Association, NASA Johnson Space
Center, Houston, Texas. She also collaborates or directs with Dr. Kajander,
nanobacterial research projects at more than 100 sites.

     Dr. Ciftcioglu holds an undergraduate degree from Kocatepe Mimar Kemal
Lisesi, in Ankara, Turkey and both a master's degree and a doctorate degree in
microbiology from the University of Ankara. She served as a post-doctoral
research fellow in Dr. Kajander's research group at the University of Kuopio.

     Dr. Ciftcioglu's work has been recognized through a number of scientific
awards including the 1993, 1996 and 1998 Savon Korkean Teknologian Saatio Award
(Finland) and the 1997 and 1998 Jenny ja Antti Wihurin Rahasto Award (Finland).
She was also awarded the 1999 Minerva, Medix Prize for the most prominent
Finnish biomedical paper of 1998. Dr. Ciftcioglu has authored or co-authored 46
scientific publications and 17 scientific abstract communications.

     She is a professional member of NABI (NASA Astrobiology Institute), the
American Society for Microbiology, the American Society for Cell Biology, the
Societas biochemical et microbiological Fenniae and the Societas Physiologica
Finlandiae. She lectures to professional societies and universities worldwide on
the subject of nanobacteria.

     Dr. Ciftcioglu is on assignment at NASA in Houston, TX at this time. These
two scientists are recognized as the world leaders in the field of Nanobacteria
science and research.

     "We are extremely excited with our reorganized team", commented Stanton.
"We have begun the process of seating outside Directors and are working to
finalize our Advisory Board".

     Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A.
For more information, please visit our website at www.nanobaclabs.com or contact
us at info@nanobaclabs.com.

     Investors are cautioned that certain statements contained in this document
as well as some statements in periodic press releases and some oral statements
of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 (the
"Act"). Forward-Looking statements include statements which are predictive in
nature, which depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects," and
similar expressions. In addition, any statements concerning future financial
performance (including future revenues, earnings or growth rates), ongoing
business strategies or prospects, and possible future Nanobac Pharmaceuticals,
Inc. actions, which may be provided by management, are also forward-looking
statements as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which might cause the actual
results, performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by such
forward-looking statements and to vary significantly from reporting period to
reporting period. Although management believes that the assumptions will, in
fact, prove to be correct or that actual future results will not be different
from the expectations expressed in this report, these statements are not
guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no
specific intention to update these statements.

###